Table 4.
Multivariable Cox regression analysis showing the association between circulating AFABP level and incident MACE
| Model | Adjusted HR for AFABPa (95% CI) | P value |
|---|---|---|
| Model 1 | 4.25 (2.16–8.37) | < 0.01 |
| Model 2 | 2.65 (1.16–6.05) | < 0.05 |
| Model 3 | 2.77 (0.99–7.76) | 0.05 |
Model 1: include age, sex and body mass index at baseline
Model 2: include all variables in model 1 + hypertension, dyslipidemia, chronic kidney disease and glycated haemoglobin at baseline
Model 3: include all variables in model 2 + use of insulin and metformin at baseline
Hypertension was defined as BP ≥ 140/90 mmHg or the use of anti-hypertensive medications. Dyslipidemia was defined as fasting triglyceride ≥ 1.69 mmol/L, high-density lipoprotein cholesterol < 1.04 mmol/L in men and < 1.29 mmol/L in women, low-density lipoprotein cholesterol ≥ 2.6 mmol/L, or the use of lipid-lowering medications. Chronic kidney disease was defined as estimated glomerular filtration rate < 60 mL/min/1.73 m2
AFABP, adipocyte fatty acid-binding protein; CI, confidence interval; HR, hazard ratio; MACE, major adverse cardiovascular events
aLog-transformed before analysis